These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 4114458)

  • 21. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 22. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 27. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
    [No Abstract]   [Full Text] [Related]  

  • 29. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
    Goodwin FK; Brodie HK; Murphy DL; Bunney WE
    Lancet; 1970 May; 1(7653):908-11. PubMed ID: 4191547
    [No Abstract]   [Full Text] [Related]  

  • 30. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 31. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 32. Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
    Howse PM; Matthews WB
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):27-9. PubMed ID: 4570903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 34. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 35. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 36. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
    Mars H; Libman I; Schwartz AM; Gillo-Joffroy L; Barbeau A
    Can Psychiatr Assoc J; 1972 Apr; 17(2):123-31. PubMed ID: 5036506
    [No Abstract]   [Full Text] [Related]  

  • 37. Levodopa: alterations in behavior.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Clin Pharmacol Ther; 1971; 12(2):383-96. PubMed ID: 4930867
    [No Abstract]   [Full Text] [Related]  

  • 38. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 39. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 40. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.